Overview

Cannabinoid Therapy for Pediatric Epilepsy

Status:
Active, not recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1 trial to determine the tolerability and optimal dose of CBD rich cannabis extract as an adjunct treatment in children with severe drug resistant epilepsy due to Dravet Syndrome. This is an open label intervention. Study duration is 20 weeks to primary analysis with continued follow-up until 64 weeks completed.

Phase:

Phase 1

Details

Lead Sponsor:

The Hospital for Sick Children

Collaborator:

Tilray